Novel cholesterol-lowering drugs
Pro Research Analysisby 
Searched over 200M research papers
Novel Cholesterol-Lowering Drugs: Key Mechanisms and Agents
PCSK9 Inhibitors and RNA-Based Therapies for LDL Cholesterol Reduction
Recent years have seen the development of several novel cholesterol-lowering drugs that go beyond traditional statins. PCSK9 inhibitors, such as monoclonal antibodies (alirocumab, evolocumab) and small interfering RNA (siRNA) therapies like inclisiran, have shown significant LDL cholesterol (LDL-C) reduction and cardiovascular benefits. Inclisiran, in particular, offers the advantage of infrequent dosing (twice a year) and good tolerability, making it a promising option for patients who struggle with adherence to daily medications or have statin intolerance Kim2022Cupido2017Michaeli2023+6 MORE.
Bempedoic Acid and Other Small Molecule Inhibitors
Bempedoic acid, an ATP citrate lyase inhibitor, is another new agent that lowers LDL-C upstream of statins. It is especially useful for patients who cannot tolerate statins. Other small molecule inhibitors, such as gemcabene and lomitapide, target different pathways in cholesterol metabolism and provide alternatives for patients who do not respond to conventional therapies Kim2022Cupido2017Michaeli2023+5 MORE.
ANGPTL3 Inhibitors and Monoclonal Antibodies
Evinacumab, a monoclonal antibody targeting angiopoietin-like 3 (ANGPTL3), has demonstrated potent LDL-C lowering effects, particularly in patients with homozygous familial hypercholesterolemia who have limited treatment options. ANGPTL3 inhibitors can reduce both LDL-C and triglycerides, offering a dual benefit for patients with complex lipid disorders Kim2022Michaeli2023Nurmohamed2021+1 MORE.
Antisense Oligonucleotides and Gene Therapies
Antisense oligonucleotides, such as mipomersen (targeting ApoB-100), volanesorsen and olezarsen (targeting ApoC-III), and pelcarsen and olpasiran (targeting lipoprotein(a)), are emerging as targeted therapies for specific lipid abnormalities. These drugs work at the RNA level to reduce the production of atherogenic lipoproteins and are particularly valuable for patients with genetic dyslipidemias or those who do not respond to other treatments Kim2022Michaeli2023Hegele2019+1 MORE.
CETP Inhibitors and Other Emerging Agents
Cholesteryl ester transfer protein (CETP) inhibitors, such as obicetrapib, are being investigated for their ability to lower LDL-C and potentially raise HDL cholesterol. While many CETP inhibitors have failed due to lack of efficacy or safety concerns, new candidates continue to be explored Cupido2017Michaeli2023Nurmohamed2021+2 MORE.
Berberine: A Unique Mechanism
Berberine, a compound derived from Chinese herbs, has been identified as a novel cholesterol-lowering agent. It works through a unique mechanism by stabilizing LDL receptor mRNA, leading to increased LDL receptor expression and enhanced clearance of LDL-C from the bloodstream. This mechanism is distinct from that of statins and offers an alternative for patients seeking non-traditional therapies .
Conclusion
A wide range of novel cholesterol-lowering drugs has emerged, targeting various pathways involved in lipid metabolism. These include PCSK9 inhibitors (monoclonal antibodies and siRNA), bempedoic acid, ANGPTL3 inhibitors, antisense oligonucleotides, CETP inhibitors, and natural compounds like berberine. These agents provide new options for patients who are statin-intolerant, have genetic lipid disorders, or require additional LDL-C lowering beyond what statins can achieve. Ongoing clinical trials and real-world studies will further clarify their roles in cardiovascular risk reduction and routine clinical practice Kim2022Cupido2017Kong2004+7 MORE.
Sources and full results
Most relevant research papers on this topic